Exploring the effects of minor cannabinoids and terpenes on HIV-related inflammation and pain.
Anti-inflammatory Effects of Novel Minor Cannabinoids and Terpenes on Cellular and Murine Models of HIV and HIV Proteins
This study is looking at how some non-intoxicating compounds from cannabis might help reduce pain and inflammation for people living with HIV, with the goal of making their lives a little easier alongside their current treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Mississippi NIH-funded |
| Lab location | 1 site (University, United States) |
| Project ID | NIH-10663954 on NIH RePORTER |
What this research studies
This research investigates how certain minor cannabinoids and terpenes from cannabis can help reduce inflammation and pain in patients with HIV. The study focuses on compounds that do not have psychoactive effects, aiming to complement existing HIV treatments. Researchers will test these compounds in laboratory settings using human cells and mouse models to assess their potential benefits in managing HIV-related symptoms. By identifying effective cannabis constituents, the research seeks to improve the quality of life for HIV-infected individuals suffering from pain.
Who could benefit from this research
Good fit: Ideal candidates for this research are HIV-infected individuals experiencing chronic pain and currently undergoing antiretroviral therapy.
Not a fit: Patients who are not HIV-infected or those who do not experience pain related to HIV may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide new, non-psychoactive treatment options for managing pain and inflammation in HIV patients.
How similar studies have performed: Previous research has shown promise in using cannabinoids for pain management, but this specific approach focusing on minor cannabinoids and terpenes in HIV patients is relatively novel.
Where this research is happening
University, United States
- University of Mississippi — University, United States (Active)
Researchers
- Principal investigator: Paris, Jason Richard — University of Mississippi
- Study coordinator: Paris, Jason Richard
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.